[Comparative study on the saluretic activity of etacrynic acid and BAY g 2821 in patients with cardiac decompensation (author's transl)].
In a randomised double-blind comparative study 40 mg 3-amino-1-(3,4-dichloro-alpha-methyl-benzyl)-2-pyrazolin-5-one (BAY g 2821), a novel diuretic agent, were tested against 50 mg etacrynic acid in patients with cardiac decompensation. BAY g 2821 has a rapid onset of action which slowly decreases until 12 h after administration. Within a period between the second and the fourth hour after administration, the efficacy of BAY g 2821 is superior to that of etacrynic acid. The difference is statistically significant. The total elimination of BAY g 2821 is markedly more pronounced than that of etacrynic acid throughout the 5-day treatment course. Neither subjective nor objective side effects were observed.
D004232:Diuretics / Q000494:pharmacology*; D004976:Ethacrynic Acid / Q000009:adverse effects / Q000494:pharmacology*; D006331:Heart Diseases / Q000652:urine*; D006801:Humans; D011188:Potassium / Q000652:urine; D011720:Pyrazoles / Q000494:pharmacology*; D012965:Sodium Chloride / Q000652:urine*; D013997:Time Factors
D004232:Diuretics; D011720:Pyrazoles; D012965:Sodium Chloride; D004976:Ethacrynic Acid; D011188:Potassium
Saluretischer Wirkungsvergleich von Etacrynsäure mit BAY g 2821 bei Patienten mit kardialer Dekompensation.